STOCK TITAN

Syndax Pharmaceuticals Inc - SNDX STOCK NEWS

Welcome to our dedicated news page for Syndax Pharmaceuticals (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syndax Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syndax Pharmaceuticals's position in the market.

Rhea-AI Summary
Syndax Pharmaceuticals will report its Q3 2023 financial results and provide a business update on November 2. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals plans to submit a New Drug Application (NDA) for revumenib in relapsed or refractory KMT2Ar acute leukemia, including AML and ALL, under the FDA's RTOR program. The FDA's inclusion in the RTOR program follows the Breakthrough Therapy Designation for the same indication and recent positive topline data from the AUGMENT-101 pivotal trial. Syndax expects to complete the NDA submission by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals announces positive results from the AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia, meeting its primary endpoint with a CR/CRh rate of 23% (p-value = 0.0036). Syndax plans to submit FDA filings for revumenib and axatilimab by the end of 2023. Safety profile is favorable with only 6% discontinuing due to treatment-related adverse events. Syndax is funded into the second half of 2025. Revumenib shows potential as a first- and best-in-class agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.02%
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals will share topline results from the AUGMENT-101 trial in relapsed/refractory KMT2Ar acute leukemia on October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Syndax Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Syndax Pharmaceuticals CEO to participate in Targeted Oncology panel discussion at Citi BioPharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) reported positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD, with plans for two U.S. registrational filings by the end of 2023. The company also expects to share topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia in the third quarter of 2023. Syndax's financial results for the quarter ended June 30, 2023, showed increased research and development expenses, with a net loss attributable to common stockholders of $44.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) to Report Q2 2023 Financial Results and Business Update on August 3, 2023 - Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will release its second-quarter 2023 financial results and provide a business update on August 3, 2023, after the close of the U.S. financial markets. The management will also host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide further updates. Access to the webcast and conference call details are available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
Syndax Pharmaceuticals Inc

Nasdaq:SNDX

SNDX Rankings

SNDX Stock Data

1.85B
84.63M
0.82%
106.63%
11.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.